OLANZAPINE TEVA ® 15 MG

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

OLANZAPINE 15 MG

Disponible desde:

SALOMON,LEVIN & ELSTEIN LTD

Código ATC:

N05AH03

formulario farmacéutico:

FILM COATED TABLETS

Vía de administración:

PER OS

Fabricado por:

TEVA OPERATIONS POLAND SP.ZO.O

Grupo terapéutico:

OLANZAPINE

indicaciones terapéuticas:

Acute and maintenance treatment of schizophrenia. Olanzapine Teva® is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva® is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva® is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Fecha de autorización:

2011-04-01